Entrada Therapeutics Reports Strong Q4 Earnings with a Surprising GAAP EPS Performance

Thursday, 14 March 2024, 06:56

Entrada Therapeutics has outperformed analyst expectations in the fourth quarter with a positive GAAP EPS of -$0.29, beating estimates by $0.81. The company also reported revenue of $41.85 million and holds $352 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
LivaRava Finance Meta Image
Entrada Therapeutics Reports Strong Q4 Earnings with a Surprising GAAP EPS Performance

Entrada Therapeutics Q4 Earnings Report

Entrada Therapeutics recently released their Q4 financial results, showcasing a strong performance in both GAAP EPS and revenue.

Key Highlights:

  • Positive GAAP EPS: The company achieved a positive GAAP EPS of -$0.29, surpassing analyst expectations by $0.81.
  • Revenue Figures: Entrada Therapeutics reported revenue of $41.85 million in the fourth quarter.
  • Financial Position: The company holds $352 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe